Novel histone-binding C-type lectin receptors and their role in sterile inflammation and tissue injury

新型组蛋白结合 C 型凝集素受体及其在无菌炎症和组织损伤中的作用

基本信息

  • 批准号:
    10566947
  • 负责人:
  • 金额:
    $ 59.39万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-11-09 至 2027-10-31
  • 项目状态:
    未结题

项目摘要

Abstract The immune system has evolved mechanisms to recognize cell injury and in response stimulate sterile inflammation. This response contributes in important ways to both heath and disease. In this process, dying cells release Damage Associated Cell Patterns (DAMPs) that are detected by receptors on immune cells, which then trigger sterile inflammation. Histones are DAMPs that are major drivers of sterile inflammation and there is a recent growing literature implicating the release of and response to histones in the morbidity and mortality from tissue injury. Given the role of these DAMPs in the pathogenesis of disease, it is important to understand the receptors that engage these ligands and mediate their effects. Before our work, such receptors were unknown. We discovered the first cellular receptor for histones, which was the C-type lectin receptor (CLR/Clec) Clec2d. We showed that Clec2d plays an important role in innate immune responses to histones and the pathogenesis of disease in vivo. Our studies also revealed that Clec2d is not the whole story and that there must be another histone receptor(s) in mice that contributes to responses and disease. Moreover, human innate immune cells are similarly stimulated by histones, however when we went to translate our findings to humans, we found that the human homolog of Clec2d does not recognize histones. Therefore, there are as yet to be identified human histone receptors. Importantly, we have now discovered such novel Clec-histone receptors (CHRs) in both mice and humans and these discoveries form the basis for this grant application. We have two Aims: Aim 1 will elucidate the role of CHRs in innate immune responses to histones in vivo. We will define what innate immune cells use CHRs to sense histones in vivo, the nature of the subsequent responses, and their role in the sterile inflammatory response and pathogenic sequelae of tissue injury in vivo. The importance of this aim is that it will provide insight into disease pathogenesis and potentially identify new molecular targets for treating these conditions; and, Aim 2 will define the specificity, consequences and underlying mechanisms of histone stimulation of novel CHRs. The importance of this aim is that it will define the underlying mechanisms by which histones and their receptors trigger and regulate responses, which ultimately drive host defense and pathobiology.
摘要 免疫系统已经进化出识别细胞损伤并作为回应刺激不孕的机制。 发炎。这种反应对健康和疾病都有重要的贡献。在这个过程中,死亡的细胞 释放免疫细胞上的受体检测到的损伤相关细胞模式(DAMP),然后 引发无菌炎症。组蛋白是无菌炎症的主要驱动力,有一种 最近越来越多的文献表明,组蛋白的释放和对组蛋白的反应与糖尿病的发病率和死亡率有关 组织损伤。鉴于这些湿气在疾病发病机制中的作用,了解 与这些配体结合并调节其作用的受体。在我们的工作之前,这种受体是未知的。 我们发现了第一个组蛋白的细胞受体,即C型凝集素受体(CLR/CLEC)Clec2d。 我们发现,clec2d在组蛋白的先天免疫反应和发病机制中起着重要作用。 活体内的疾病。我们的研究还揭示了Clec2d并不是整个故事的全部,肯定还有另一个 小鼠体内的组蛋白受体(S),参与反应和疾病。此外,人类先天免疫细胞 同样受到组蛋白的刺激,然而当我们将我们的发现翻译到人类身上时,我们发现 Clec2d的人类同源物不识别组蛋白。因此,目前尚有尚未确定的人类 组蛋白受体。重要的是,我们现在已经在两只小鼠身上发现了这种新的CLEC-组蛋白受体(CHR) 人类和这些发现构成了这项拨款申请的基础。我们有两个目标:目标1将 阐明CHRS在体内对组蛋白的先天免疫反应中的作用。我们将定义什么是先天免疫 细胞使用CHR来感觉体内的组蛋白,随后反应的性质,以及它们在不育中的作用 活体组织损伤的炎症反应和致病后遗症。这一目标的重要性在于它将 提供对疾病发病机制的洞察,并有可能确定治疗这些疾病的新分子靶点 并且,目标2将定义组蛋白的特异性、结果和潜在机制 刺激新的CHRS。这一目标的重要性在于,它将定义基本机制, 组蛋白及其受体触发和调节反应,最终推动宿主防御和 病理生物学。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KENNETH L ROCK其他文献

KENNETH L ROCK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KENNETH L ROCK', 18)}}的其他基金

Role of IRF2 in cancer immune evasion and immunotherapy
IRF2在癌症免疫逃避和免疫治疗中的作用
  • 批准号:
    10204986
  • 财政年份:
    2020
  • 资助金额:
    $ 59.39万
  • 项目类别:
Role of IRF2 in cancer immune evasion and immunotherapy
IRF2在癌症免疫逃避和免疫治疗中的作用
  • 批准号:
    10414938
  • 财政年份:
    2020
  • 资助金额:
    $ 59.39万
  • 项目类别:
Role of IRF2 in cancer immune evasion and immunotherapy
IRF2在癌症免疫逃避和免疫治疗中的作用
  • 批准号:
    10667446
  • 财政年份:
    2020
  • 资助金额:
    $ 59.39万
  • 项目类别:
Mechanisms of cross-presenting antigens in phagosomes on MHC I molecules to stimulate CD8 T lymphocyte responses
MHC I分子上的吞噬体中交叉呈递抗原刺激CD8 T淋巴细胞反应的机制
  • 批准号:
    9797712
  • 财政年份:
    2019
  • 资助金额:
    $ 59.39万
  • 项目类别:
Mechanisms of cross-presenting antigens in phagosomes on MHC I molecules to stimulate CD8 T lymphocyte responses
MHC I分子上的吞噬体中交叉呈递抗原刺激CD8 T淋巴细胞反应的机制
  • 批准号:
    10392945
  • 财政年份:
    2019
  • 资助金额:
    $ 59.39万
  • 项目类别:
Mechanisms of cross-presenting antigens in phagosomes on MHC I molecules to stimulate CD8 T lymphocyte responses
MHC I分子上的吞噬体中交叉呈递抗原刺激CD8 T淋巴细胞反应的机制
  • 批准号:
    10606598
  • 财政年份:
    2019
  • 资助金额:
    $ 59.39万
  • 项目类别:
Role of Clec2d-DAMP interactions in the pathophysiology of tissue injury and sepsis
Clec2d-DAMP 相互作用在组织损伤和脓毒症病理生理学中的作用
  • 批准号:
    10164709
  • 财政年份:
    2017
  • 资助金额:
    $ 59.39万
  • 项目类别:
Role of Tspan5 in MHC I antigen presentation and cancer immune evasion
Tspan5 在 MHC I 抗原呈递和癌症免疫逃避中的作用
  • 批准号:
    10210168
  • 财政年份:
    2016
  • 资助金额:
    $ 59.39万
  • 项目类别:
Role of Tspan5 in MHC I antigen presentation and cancer immune evasion
Tspan5 在 MHC I 抗原呈递和癌症免疫逃避中的作用
  • 批准号:
    10362713
  • 财政年份:
    2016
  • 资助金额:
    $ 59.39万
  • 项目类别:
Elucidation of the role of 2 novel cross presentation genes
阐明 2 个新型交叉表达基因的作用
  • 批准号:
    9883698
  • 财政年份:
    2016
  • 资助金额:
    $ 59.39万
  • 项目类别:

相似海外基金

Establishment of a method for evaluating automobile driving ability focusing on frontal lobe functions and its application to accident prediction
以额叶功能为中心的汽车驾驶能力评价方法的建立及其在事故预测中的应用
  • 批准号:
    20K07947
  • 财政年份:
    2020
  • 资助金额:
    $ 59.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Evaluation of the Effectiveness of Multi-Professional Collaborative Assessment of Cognitive Function and Automobile Driving Skills and Comprehensive Support
认知功能与汽车驾驶技能多专业协同评估效果评价及综合支持
  • 批准号:
    17K19824
  • 财政年份:
    2017
  • 资助金额:
    $ 59.39万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Development of Flexible Automobile Driving Interface for Disabled People
残疾人灵活汽车驾驶界面开发
  • 批准号:
    25330237
  • 财政年份:
    2013
  • 资助金额:
    $ 59.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Automobile driving among older people with dementia: the effect of an intervention using a support manual for family caregivers
患有痴呆症的老年人的汽车驾驶:使用家庭护理人员支持手册进行干预的效果
  • 批准号:
    23591741
  • 财政年份:
    2011
  • 资助金额:
    $ 59.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了